Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 17 September 2019, 15:42 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan

TOKYO, Sept 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan.

The IIA Japan was established in 1957 with the aim of contributing to the sound development of Japan's industry and economy through the internal audits. It also functions as Japan's representative organization of The Institution of Internal Auditors (IIA), which plays a role of global leadership in international audits.

"IIA Japan Chairman's Award" was established in 1987, and it is the 33rd time this year. This award is to commend the corporations and management organizations, which have the fulfilled internal audit system, the active and continuous internal audit activities in long time period, the achieved results, as well as the contribution for spreading and developing the internal audit.

Through the review by the Review Committee, the following initiatives of Eisai's Corporate Internal Audit Department for the internal audit activities were highly evaluated, and Eisai received the Chairman's Award.

- Emphasis on contribution for achieving the corporate objectives
- Implementation of audit by the full consideration of business operation risks and socially focused matters and selecting the theme for audit
- Emphasis on cause analysis of problems
- Implementation of regular internal and external evaluations for continuous audit quality improvement

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. In order to realize this corporate philosophy, Eisai will promote our initiatives for internal audit quality improvement, and is striving for further enhancement of corporate governance to improve sustainable corporate value.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 12, 2026 16:21 HKT/SGT
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 11, 2026 11:07 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 2, 2026 08:49 HKT/SGT
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Feb 16, 2026 13:03 HKT/SGT
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 10, 2026 12:34 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 10:31 HKT/SGT
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 26, 2026 10:37 HKT/SGT
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 21, 2026 15:44 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 13, 2026 08:50 HKT/SGT
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 6, 2026 09:43 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: